Immunterapi er kræftbehandling med en helt ny bivirkningsprofil
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.
Bidragets oversatte titel | Immunotherapy is cancer treatment with a novel side-effect profile |
---|---|
Originalsprog | Dansk |
Artikelnummer | V05170365 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 179 |
Antal sider | 5 |
ISSN | 0041-5782 |
Status | Udgivet - 2017 |
- Antibodies, Monoclonal/adverse effects, Antineoplastic Agents, Immunological/adverse effects, CTLA-4 Antigen/antagonists & inhibitors, Chemical and Drug Induced Liver Injury/etiology, Drug-Related Side Effects and Adverse Reactions/diagnostic imaging, Endocrine System Diseases/chemically induced, Gastrointestinal Diseases/chemically induced, Humans, Immunotherapy/adverse effects, Lung Diseases/chemically induced, Mobile Applications, Neoplasms/drug therapy, Practice Guidelines as Topic, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Skin Diseases/chemically induced, Tomography, X-Ray Computed
Forskningsområder
Links
- http://ugeskriftet.dk/videnskab/immunterapi-er-kraeftbehandling-med-en-helt-ny-bivirkningsprofil
Forlagets udgivne version
ID: 215863643